| Literature DB >> 31719025 |
Hans Vehof1,2, Eibert Heerdink2,3, José Sanders1, Enny Das1.
Abstract
BACKGROUND: Although experts agree that Web-based health information often contains exaggeration and misrepresentation of science, it is not yet known how this information affects the readers' sentiments.Entities:
Keywords: diabetes mellitus; diffusion of innovation; information seeking behaviors; medical journalism; news
Mesh:
Year: 2019 PMID: 31719025 PMCID: PMC6881782 DOI: 10.2196/14554
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Overview of the data extraction and preparation. JDRF: Juvenile Diabetes Research Foundation.
A total of 5 categories of intended diabetes research effects with examples.
| Intended effect | Examples |
| Prevention | Research into a viral trigger for type 1 diabetes; effects of hygiene; nanotechnology; and early diagnosis |
| Practical solution | Hypoglycemia alarm watch; an insulin temperature sensor; hypoglycemia watchdog; glucose monitoring app; and diabetic shoe |
| Symptom control and relief | Cognitive behavioral therapy; research on nephropathy; and research on cardiomyopathy in type 2 diabetes |
| Glucose regulation | Artificial pancreas; inhalable insulin; Cone Insulin G1; and an insulin delivery system |
| Diabetes cure | Beta cell encapsulation; viral gene transfer; the discovery of immature beta cells; transplanting pancreatic cells; and the effects of vitamin D |
The number of extracted news posts and user comments by the innovations’ intended therapeutic effect and developmental phase, and the number of comment sentiments.
| News characteristics and comment sentiments | News posts, n | User comments, n (%) | Comments per post, mean | |
| Total | 173 | 3710 (100) | 21 | |
|
| ||||
|
| Disease prevention | 16 | 211 (5.69) | 13 |
|
| Practical solution | 14 | 250 (6.74) | 18 |
|
| Symptom relief | 11 | 182 (4.91) | 17 |
|
| Improved glucose regulation | 56 | 1341 (36.15) | 24 |
|
| Cure | 76 | 1726 (46.52) | 23 |
|
| ||||
|
| Evidence from fundamental research | 47 | 859 (23.15) | 18 |
|
| Evidence from pretrial phases | 32 | 758 (20.43) | 24 |
|
| Evidence from small human trials | 33 | 712 (19.19) | 22 |
|
| Evidence from large human trials | 10 | 434 (11.70) | 43 |
|
| Near-market entry | 14 | 259 (6.98) | 19 |
|
| Evidence from observational studies | 12 | 185 (4.99) | 15 |
|
| Not described | 25 | 503 (13.56) | 20 |
|
| ||||
|
| Positive only | —a | 2467 (66.50) | — |
|
| Negative only | — | 620 (16.71) | — |
|
| Mixed positive and negative | — | 260 (7.01) | — |
|
| Positive, including mixed | — | 2727 (73.50) | — |
|
| Negative, including mixed | — | 880 (23.72) | — |
|
| Neutral | — | 363 (9.78) | — |
|
| Verbal expressions of | — | 513 (13.83) | — |
aNot applicable.
Logistic regression analysis of the association among 3 characteristics of diabetes news in Facebook posts (mutually adjusted) and positive and negative sentiments in the user comments on Facebook pages.
| News characteristics | Facebook posts, n | Positive sentiment | Negative sentiment | |||||
| Yes, n (%) | No, n (%) | ORa (95% CI) | Yes, n (%) | No, n (%) | OR (95% CI) | |||
|
| ||||||||
|
| Diabetes prevention | 16 | 94 (3.45) | 117 (11.90) | 0.55b (0.37-0.84) | 85 (9.66) | 126 (4) | 1.48 (0.98-2.25) |
|
| Practical solutions | 14 | 196 (7.19) | 54 (5.49) | 1.01 (0.71-1.44) | 52 (5.91) | 198 (7) | 1.01 (0.71-1.45) |
|
| Symptom relief | 11 | 86 (3.15) | 96 (9.77) | 0.31b (0.21-0.44) | 49 (5.57) | 133 (5) | 1.24 (0.84-1.82) |
|
| Blood glucose regulation | 56 | 970 (35.57) | 371 (37.74) | 0.68b (0.56-0.84) | 343 (38.98) | 998 (35) | 1.38b (1.12-1.70) |
|
| Diabetes cure | 76 | 1381 (50.64) | 345 (35.10) | 1.0c | 351 (39.89) | 1375 (49) | 1.0c |
|
| ||||||||
|
| Observational evidence | 12 | 61 (2.24) | 124 (12.61) | 0.31b (0.15-0.66) | 79 (8.98) | 106 (3.75) | 1.88b (1.17-3.02) |
|
| Fundamental evidence | 47 | 610 (22.37) | 249 (25.33) | 0.71b (0.53-0.95) | 238 (27.05) | 621 (21.94) | 1.22 (0.92-1.63) |
|
| Preclinical evidence | 32 | 639 (23.43) | 119 (12.11) | 1.46b (1.07-1.99) | 112 (12.73) | 646 (22.83) | 0.55b (0.41-0.76) |
|
| Small trial evidence | 33 | 541 (19.84) | 171 (17.40) | 1.06 (0.80-1.42) | 147 (16.70) | 565 (19.96) | 0.75b (0.56-1.00) |
|
| Large trial evidence | 10 | 317 (11.62) | 117 (11.90) | 1.0c | 115 (13.07) | 319 (11.27) | 1.0c |
|
| Near-market entry | 14 | 175 (6.42) | 84 (8.55) | 0.73 (0.52-1.04) | 70 (7.95) | 189 (6.68) | 1.39 (0.90-2.14) |
|
| Not mentioned | 25 | 384 (14.08) | 119 (12.11) | 1.03 (0.76-1.40) | 119 (13.52) | 384 (13.57) | 0.96 (0.71-1.31) |
|
| ||||||||
|
| 3-9 intensifiers | 21 | 380 (13.93) | 156 (15.87) | 0.97 (0.75-1.25) | 132 (15.00) | 404 (14.28) | 1.12 (0.86-1.45) |
|
| 1-2 intensifiers | 55 | 1120 (41.07) | 314 (31.94) | 1.13 (0.94-1.35) | 334 (37.95) | 1100 (38.87) | 1.18 (0.99-1.42) |
|
| 0 intensifiers | 97 | 1227 (44.99) | 513 (52.19) | 1.0c | 414 (47.05) | 1326 (46.86) | 1.0c |
aOR: odds ratio.
bStatistically significant odds ratio.
cFor reference category, CI is not applicable.
dText intensifiers were a nonsignificant addition to this model but were left in the model to answer study questions.
Logistic regression analysis of the association among 3 characteristics of diabetes news in Facebook posts (mutually adjusted) and expressed hopefulness (eg, hopefully and I hope) in the user comments on Facebook pages.
| News characteristics | News posts, n | Textual expression of hopefulness | |||
| Yes, n (%) | No, n (%) | ORa (95% CI) | |||
|
| |||||
|
| Prevention | 16 | 15 (2.92) | 196 (6.13) | 0.92 (0.50-1.72) |
|
| Practical solution | 14 | 10 (1.95) | 240 (7.51) | 0.18b (0.09-0.36) |
|
| Symptom relief | 11 | 4 (0.78) | 178 (5.57) | 0.13b (0.05-0.36) |
|
| Glucose regulation | 56 | 136 (26.51) | 1205 (37.69) | 0.49b (0.38-0.64) |
|
| Diabetes cure | 76 | 348 (67.84) | 1378 (43.10) | 1.0c |
|
| |||||
|
| Observational evidence | 12 | 2 (0.39) | 183 (5.72) | 0.07b (0.02-0.33) |
|
| Fundamental evidence | 47 | 133 (25.93) | 726 (22.71) | 0.97 (0.65-1.43) |
|
| Preclinical evidence | 32 | 164 (31.97) | 594 (18.58) | 1.47b (1.01-2.14) |
|
| Small trial evidence | 33 | 96 (18.71) | 616 (19.27) | 1.26 (0.85-1.87) |
|
| Large trial evidence | 10 | 46 (8.97) | 388(12.14) | 1.0c |
|
| Near-market entry | 14 | 18 (3.51) | 241 (7.54) | 0.89 (0.49-1.59) |
|
| Not described | 25 | 54 (10.53) | 449 (14.04) | 0.93 (0.61-1.43) |
|
| |||||
|
| 3-10 intensifiers | 21 | 80 (15.59) | 456 (14.26) | 1.15 (0.84-1.58) |
|
| 1-2 intensifiers | 55 | 242 (47.17) | 1192 (37.28) | 1.09 (0.87-1.36) |
|
| 0 intensifiers | 97 | 191 (37.23) | 1549 (48.45) | 1.0c |
aOR: odds ratio.
bStatistically significant odds ratio.
cFor reference category, CI is not applicable.
dText intensifiers were a nonsignificant addition to this model but were left in the model to answer the study question.